| scholarly article | Q13442814 |
| P2093 | author name string | Omkar Gandbhir | |
| Pazhani Sundaram | |||
| P2860 | cites work | Click Conjugation of Cloaked Peptide Ligands to Microbubbles | Q88256672 |
| Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy | Q88394520 | ||
| Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab | Q88732343 | ||
| Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 | ||
| Click chemistry in peptide-based drug design | Q26853053 | ||
| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Q28005463 | ||
| Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis | Q30457367 | ||
| Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display | Q30975381 | ||
| Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. | Q31840691 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| 2012 Alzheimer's disease facts and figures | Q34260109 | ||
| A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease | Q34575658 | ||
| Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States | Q35133019 | ||
| Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice | Q35747037 | ||
| Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. | Q36996040 | ||
| A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo | Q37157963 | ||
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. | Q37391481 | ||
| Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. | Q37572741 | ||
| Development and mechanism of γ-secretase modulators for Alzheimer's disease | Q38101383 | ||
| Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study | Q38229421 | ||
| Patents on potential drugs to treat Alzheimer's disease: special emphasis on small peptides | Q38253144 | ||
| Strategic approaches to optimizing peptide ADME properties | Q38264736 | ||
| Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer's Disease | Q38775329 | ||
| Recent developments in retro peptides and proteins--an ongoing topochemical exploration | Q40405029 | ||
| Novel Detox Gel Depot sequesters β-Amyloid Peptides in a mouse model of Alzheimer's Disease | Q42146308 | ||
| Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease | Q42656054 | ||
| A new roadmap for drug development for Alzheimer's disease | Q43144647 | ||
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
| Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization | Q44833066 | ||
| Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers. | Q48327869 | ||
| Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. | Q48406875 | ||
| Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide | Q48442287 | ||
| ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. | Q52562915 | ||
| The Effect of Chronic Cerebral Hypoperfusion on Amyloid-β Metabolism in a Transgenic Mouse Model of Alzheimer's Disease (PS1V97L). | Q52609738 | ||
| Detoxification depot for beta-amyloid peptides. | Q53292384 | ||
| Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy. | Q54237920 | ||
| 'Amytrapper', a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation | Q64237560 | ||
| A comparison of the immunogenicity of a pair of enantiomeric proteins | Q72868496 | ||
| On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules | Q73428233 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 77-94 | |
| P577 | publication date | 2019-05-06 | |
| P1476 | title | Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer's Disease | |
| P478 | volume | 3 |
Search more.